Treatment of adolescents with early-onset schizophrenia spectrum disorders: In search of a rational, evidence-informed approach

Current Opinion in Psychiatry

Volumn 26, Issue 2, 2013, Pages 219-230

  Schimmelmann, Benno G ^a   Schmidt, Stefanie J ^a   Carbon, Maren ^b   Correll, Christoph U ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

adolescence; cognitive behavioural therapy; paediatrics; psychopharmacology; psychosis

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; ILOPERIDONE; LURASIDONE; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; ADOLESCENT DISEASE; AKATHISIA; ANTICHOLINERGIC EFFECT; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COGNITIVE REHABILITATION; COGNITIVE REMEDIATION; COGNITIVE THERAPY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG TOLERABILITY; DYSKINESIA; EARLY ONSET SCHIZOPHRENIA; FAMILY THERAPY; HUMAN; JUVENILE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NEUTROPENIA; ONSET AGE; ORTHOSTATIC INTOLERANCE; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PROBLEM SOLVING; PSYCHOEDUCATION; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOSOCIAL CARE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RECREATION; REVIEW; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN; WITHDRAWAL DYSKINESIA;

ADOLESCENT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84873367365     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32835dcc2a     Document Type: Review

References (67)

1. Hollis C. Adult outcome of child- and adolescent-onset schizophrenia: Diagnostic stability and predictive validity. Am J Psychiatry 2000; 157: 1652-1659
2. Castro-Fornieles J, Parellada M, Gonzalez-Pinto A, et al. The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline results. Schizophr Res 2007; 91:226-237 (Pubitemid 46343653)
3. Schimmelmann BG, Conus P, Edwards J, et al. Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry 2005; 66:1239-1246 (Pubitemid 41546503)
4. Correll CU, Lencz T, Smith CW, et al. Prospective study of adolescents with subsyndromal psychosis: Characteristics and outcome. J Child Adolesc Psychopharmacol 2005; 15:418-433 (Pubitemid 41192829)
5. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of secondgeneration antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008; 34:60-71 (Pubitemid 350262286)
6. Häfner H, Maurer K, Löffler W. Onset and early course of schizophrenia. In: Häfner H, Gattez WF, editors. Search for the causes of schizophrenia. 3rd ed. Berlin, Heidelberg: Springer; 1995. pp. 43-66
7. Hans SL, Auerbach JG, Arsanow JR, et al. Social adjustment of adolescents at risk for schizophrenia: The Jerusalem Infant Development Study. J Am Acad Child Adolesc Psychiatry 2000; 39:1406-1414
8. Joa I, Johannessen JO, Langeveld J, et al. Baseline profiles of adolescent vs. adult-onset first-episode psychosis in an early detection program. Acta Psychiatr Scand 2009; 119:494-500
9. Ballageer T, Malla A, Manchanda R, et al. Is adult-onset first-episode psychosis different from adult onset? J Am Acad Child Adolesc Psychiatry 2005; 44:782-789 (Pubitemid 41026282)
10. Basso MR, Nasrallah HA, Olson SC, et al. Cognitive deficits distinguish patients with adolescent- and adult-onset schizophrenia. Neuropsychiatry Neuropsychol Behav Neurol 1997; 10:107-112 (Pubitemid 27211965)
11. Vyas NS, Patel NH, Puri BK. Neurobiology and phenotypic expression in early onset schizophrenia. Early Interv Psychiatry 2011; 5:3-14
12. Reichert A, Kreiker S, Mehler-Wex C, Warnke A. The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child Adolesc Psychiatry Ment Health 2008; 2:6
13. Amminger GP, Henry LP, Harrigan SM, et al. Outcome in early-onset schizophrenia revisited: Findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr Res 2011; 131:112-119
14. Schimmelmann BG, Conus P, Cotton S, et al. Pretreatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res 2007; 95:1-8 (Pubitemid 47315740)
15. Schimmelmann BG, Huber CG, Lambert M, et al. Impact of duration of untreated psychosis on pretreatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008; 42:982-990
16. Ueland T, Rund BR. A controlled randomized treatment study: The effects of a cognitive remediation program on adolescents with early onset psychosis. Acta Psychiatr Scand 2004; 109:70-74 (Pubitemid 38161103)
17. Ueland T, Rund BR. Cognitive remediation for adolescents with early onset psychosis: A 1-year follow-up study. Acta Psychiatr Scand 2005; 111:193- 201 (Pubitemid 40342187)
18. Wykes T, Newton E, Landau S, et al. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: An exploratory randomized controlled trial. Schizophr Res 2007; 94:221-230 (Pubitemid 47031576)
19. Urben S, Pihet S, Jaugey L, et al. Computer-assisted cognitive remediation in adolescents with psychosis or at risk for psychosis: A 6-month follow-up. Acta Neuropsychiatrica 2012; 24:328-335
20. Jenner JA, van de Willige G. HIT, hallucination focused integrative treatment as early intervention in psychotic adolescents with auditory hallucinations: A pilot study. Acta Psychiatr Scand 2001; 103:148-152 (Pubitemid 32147136)
21. Wragg JA, Whitehead RE. CBT for adolescents with psychosis: Investigating the feasibility and effectiveness of early intervention using a single case design. Behav Cogn Psychother 2004; 32:313-329 (Pubitemid 38931726)
22. Bechdolf A, Tecic T, Lehnkuhl G, et al. Cognitive behavior therapy in adolescents with persistent symptoms. Results of a randomized trial. Eur Arch Psychiatry Clin Neurosci 2011; 261 (Suppl. 1):7-101
23. Rund BR, Meo L, Sollien T, et al. The Psychosis Project: Outcome and costeffectiveness of a psychoeducational treatment programme for schizophrenic adolescents. Acta Psychiatr Scand 1994; 89:211-218 (Pubitemid 24074838)
24. Jackson HJ, McGorry PD, Killackey E, et al. Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for firstepisode psychosis: The ACE project. Psychol Med 2008; 38:725-735 (Pubitemid 351483239)
25. Power PJ, Bell RJ, Mills R, et al. Suicide prevention in first episode psychosis: The development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Aust N Z J Psychiatry 2003; 37:414-420 (Pubitemid 37121574)
26. Jones C, Hacker D, Cormac I, et al. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [review]. Cochrane Database Syst Rev 2012; 4:CD008712
27. Linszen D, Dingemans P, Lenior ME. Early intervention and a five-year followup in young adults with a short duration of untreated psychosis: Ethical implications. Schizophr Res 2001; 51:55-61 (Pubitemid 32722069)
28. Zhang M, Wang M, Li J, et al. Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients: An 18-month study in Suzhou, Jiangsu. Brit J Psychiatry 1994; 165:96-102 (Pubitemid 24259374)
29. Bird V, Premkumar P, Kendall T, et al. Early intervention services, cognitive behavioural therapy and family intervention in early psychosis: A systematic review. Brit J Psychiatry 2010; 197:350-356
30. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized doubleblind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165:1432-1441
31. Kryzhanovskaya L, Schulz C, McDougle C, et al. Olanzapine vs. placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo- controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48:60-70
32. Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 2011; 70:1179-1187
33. Findling RL, Mckenna K, Earley WR, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, randomized, placebo-controlled trial. J Child Adolesc Psychopharmacol 2012; 22:327-342
34. Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009; 19:611-621
35. Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: Double-blind study. Br J Psychiatry 2009; 194:158-164
36. Findling RL, Cavusz I, Pappadopulos E, et al. A placebo-controlled trial to evaluate the efficacy and safety of flexibly dosed oral ziprasidone in adolescent subjects with schizophrenia. Schizophr Res 2012; 117:437
37. Correll CU, Kratochvil CJ, March J. Developments in pediatric psychopharmacology: Focus on stimulants, antidepressants and ntipsychotics. J Clin Psychiatry 2011; 72:655-670
38. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29:133-145 (Pubitemid 38068023)
39. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of firstand second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165:1420-1431
40. Arango C, Robles O, Parellada M, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 2009; 18:418-428
41. Jensen JB, Kumra S, Leitten W, et al. A comparative pilot study of secondgeneration antipsychotics in children and adolescents with schizophreniaspectrum disorder. J Child Adolesc Psychopharmacol 2008; 18:317-326
42. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53:1090-1097 (Pubitemid 26422059)
43. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: A doubleblind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006; 63:721-730
44. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and 'high-dose' olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison. Biol Psychiatry 2008; 63:524-529 (Pubitemid 351220784)
45. Correll CU. Antipsychotic medications: Typical and atypical. In: Martin A, Scahill L, Kratochvil CJ, editors. Pediatric sychopharmacology: Rinciples and practice. 2nd ed. New York: Oxford University Press; 2011. pp. 312- 337
46. Correll CU, Kane JM. One-year tardive dyskinesia rates in children and adolescents treated with second-generation antipsychotics. A systematic review. J Child Adolesc Psychopharmacol 2007; 17:647-655 (Pubitemid 350058977)
47. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765-1773
48. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45:771-791 (Pubitemid 43932904)
49. Kryzhanovskaya LA, Xu W, Millen BA, et al. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 2012; 22:157-165
50. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8:114-126
51. De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011; 26:144-158
52. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011; 17:97-107
53. Correll CU. From receptor pharmacology to improved outcomes: Individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010; 25:12-21
54. Correll CU. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47:9-20
55. Barnes TRE. Abnormal involuntary movement scale. A rating scale for druginduced akathisia. Br J Psychiatry 1989; 154:672-676
56. Guy WA. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health Education and Welfare; 1976. pp. 534-537
57. Simpson GM, Angus JWS. A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand 1970; 212:44-51
58. Manu P, Correll CU, Wampers M, et al. Prediabetic increase in haemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs. Eur Neuropsychopharmacol 2012. [Epub ahead of print]
59. Ho J, Panagiotopoulos C, McCrindle B, et al. Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J Can Acad Child Adolesc Psychiatry 2011; 20:234-241
60. Schimmelmann BG, Paulus S, Schacht M, et al. Subjective distress related to side effects and subjective well being in first admitted adolescents with early onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol 2005; 15:249-258 (Pubitemid 40734104)
61. Kishimoto T, de Hert M, Carlson HE, et al. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry 2012; 25:415-429
62. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of nonpharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophr Res 2012; 140:159-168
63. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophr Bull 2004; 30:193-217
64. De Hert M, van Winkel R, Wampers M, et al. Remission criteria for schizophrenia: Evaluation in a large naturalistic cohort. Schizophr Res 2007; 92:68-73 (Pubitemid 46561226)
65. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 82: Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care, 2009. http://publications.nice.org.uk/schizophrenia-cg82. [Accessed 18 December 2012]
66. Leucht S, Correll CU, Kane JM. Approaches to treatment resistant patients. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. 3rd ed. West Sussex: Blackwell Publishing Ltd; 2011. pp. 540-560
67. Lambert M, Bock T, Schöttle D, et al. Assertive Community Treatment (ACT) as part of integrated care vs. standard care: A 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry 2010; 71:1313-1323.